Serono Investors Are Looking
For an Elusive Shot in the Arm

Just about now, Serono investors are looking for a shot in the arm. They aren't likely to get it any time soon.

The Swiss biotechnology company's third-quarter results were poor. The stock fell 18% in three days of trading after the disappointing results were reported Oct. 24, but has been climbing back in recent days. On Tuesday, the stock rose 1% to 1,765 Swiss francs ($999.36, 1,159.89 euros), up 17 francs. It should have stayed...